Q-omics provides the consensus-scored TEX26 profile across patient tissues and cancer cell-line models. TEX26 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, TEX26 is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, TEX26 RNA expression shows 9,495 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight MESO, LIHC, and TGCT as cancer lineages where TEX26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TEX26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TEX26 survival associations across molecular data types. TEX26 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TEX26 RNA expression–survival associations across cancer types. High TEX26 expression shows unfavorable associations in LGG and KIRP, but favorable associations in MESO, SARC, UCS and SKCM. The MESO Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for TEX26 RNA expression.
This table summarizes TEX26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for TEX26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TEX26 shows lower tumor expression in LIHC, KIRC, BRCA, KICH, LUSC and STAD. The LIHC box plot shows higher TEX26 RNA expression in normal versus tumor tissue (log2 FC = −0.393, t-test p < 0.001).
This table shows molecular features associated with TEX26 in patient tissues and cancer cell lines. In patient samples, TEX26 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TEX26 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LIVER and SOFT_TISSUE.
